

Antimicrobial stewardship - NICE medicines practice guideline

Guideline development group (GDG) meeting 2
10am – 4pm, 8 September 2014, Manchester

Minutes: Final and confirmed

Guideline development group members present:

Chris Cefai (CC)	Present for notes 2 – 15
Esmita Charani (EC)	
Lynne Craven (LC)	
Martin Duerden (MD)	
Heather Edmonds (HE)	
Rose Gallagher (RG)	
Alastair Hay (AH, Chair)	Present for notes 3 – 15
Philip Howard (PH)	Present for notes 1 – 9
Sanjay Kalra (SK)	
Tessa Lewis (TL, Vice-chair)	
Kym Lowder (KL)	
Clodna McNulty (CM)	Present for notes 3 – 15
John Morris (JM)	
Sanjay Patel (SP)	
Wendy Thompson (WT)	
Susan Walsh (SW)	

NICE staff in attendance:

Lynda Ayiku (LA, guidance information services)
Anne-Louise Clayton (ALC, publishing)
Leighton Coombs (LCo, project team)
Jenny Craven (JC, guidance information services)
Charlotte Haynes (CH, public health)
Johanna Hulme (JH, project lead)
Dominick Moran (DM, project team)
Greg Moran (GM, project team)
Ian Pye (IP, project team)
Robby Richey (RRi, project team),
Rebekah Robinson (RR, project team)

Notes

1. TL welcomed the group to the second meeting of this GDG. The Vice-chair asked all GDG members to briefly introduce themselves to each other.
2. TL asked if any GDG members had any new or altered declarations of interest. PH notified the group that he was involved in paid consultancy work on pipeline agents with Sanofi (Europe), an AMS group with Danone, lecturing, consultancy and sponsored conference attendance. JH reiterated the importance that work from this group is not shared

with other work members are involved with. SP declared that he had worked as a scientific advisor with Thermo Fischer and written a paper on AMS. WT declared she had had a relevant journal article published. RG asked if she needed to declare an RCN published position statement which had been sponsored by Pfizer, she was advised to declare this CC informed the GDG that his previously declared potential involvement in work with Daptomycin had come to nothing and therefore this should be removed as a potential conflict of interest from this point.

3. The notes of the previous meeting were agreed as an accurate record.
4. CH provided a brief update in about the related public health guidance also being developed.
5. JH reminded the GDG of the process for reviewing the evidence for each review question and of the GDG's role.
6. GM presented the clinical evidence for review question (c) and responded to any questions from the GDG.
7. GM presented the economic evidence for review question (c) and responded to any questions from the GDG.
8. ALC presented guidance on writing and presenting recommendations in NICE guidelines.
9. The GDG discussed the evidence presented for review question (c) and began the drafting of recommendations.
10. JH reminded the GDG of the NICE equality scheme and obligations on equality and discrimination. JH asked the GDG to inform the NPT if they identify any issues that should be included on the equality impact assessment.
11. JH explained the process for forming recommendations when there may be a lack of relevant published evidence.
12. RRi gave a brief update on the progress for review question (a). DM gave a brief update on the progress for review question (b).
13. The GDG agreed the review protocol for review question (d).
14. RR passed out a draft structure for the full guideline to inform the GDG regarding what content will be included in the full guideline once published.
15. JH summarised the next steps of the development process.

Date, time and venue of the next meeting:

16. Tuesday 30 September 2014, 10am – 4pm, Manchester